Abstract
New therapeutic strategies are needed to combat the pandemics and the spread of multidrug resistant form of tuberculosis. This study aims to decipher the molecular interaction of promising new antituberculosis clinical compounds and their bacterial target. Using an original and efficient method of phenotypic high-content screening, our colleagues of Institut Pasteur of Korea have identified these new compounds which block Mycobacterium tuberculosis growth at low concentrations. All of these drugs target the cytochrome bc1 membrane complex, which is an essential component of the electron transport chain required to produce energy for bacterial metabolism 1. NMR is used to analyse the mechanism of the drug-target interaction at the atomic scale within whole live Mycobacterium cells using the innovative so called in-cell NMR method. The detailed information obtained by this study will orient drug synthesis and development of efficient therapeutic strategies.1. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, et al. (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med. 19(9):1157-60.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
